Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 37.8259
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 899558538521.0
- FreeCF/Share 10.0576
- PFCF 99.7216
- PE 48.8811
- Debt/Assets 0.3698
- DivYield 0.006
- ROE 1.0226
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LLY | UBS | -- | Buy | -- | $1250 | Jan. 7, 2026 |
| Upgrade | LLY | Daiwa Securities | Neutral | Buy | -- | $1230 | Dec. 16, 2025 |
| Reiterated | LLY | BofA Securities | -- | Buy | $1286 | $1268 | Dec. 15, 2025 |
| Reiterated | LLY | Goldman | -- | Buy | $951 | $1145 | Dec. 15, 2025 |
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
News
Calls of the Day: Live Nation, Eli Lilly, AT&T, Adobe and Astera Labs
Published: February 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss the latest Calls of the Day.
Read More
LLY Rises More Than 4% in a Week: How to Play the Stock
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Read More
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Published: February 13, 2025 by: MarketBeat
Sentiment: Positive
Eli Lilly and Company NYSE: LLY is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close.
Read More
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Published: February 13, 2025 by: The Motley Fool
Sentiment: Positive
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (LLY 0.92%) announced its full results and reiterated its earlier 2025 forecast. The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000